Micafungina Hikma

Micafungin Sodium, the active ingredient in Micafungina Hikma, is an echinocandin presented as an intravenous solution for intravenous use. It is employed to treat invasive candidiasis, esophageal candidiasis, and to provide prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungina Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our quality‑assured batches meet EU market standards and are shipped under controlled conditions to ensure product integrity through a robust cold‑chain logistics network.

Micafungin Sodium is an echinocandin antifungal used to manage invasive fungal infections, including bloodstream, deep‑tissue, and mucosal Candida disease. - Invasive candidiasis: intravenous therapy that clears bloodstream and deep‑tissue Candida infections, reducing mortality in immunocompromised patients. - Esophageal candidiasis: targeted treatment that eliminates Candida lesions in the esophagus, improving swallowing and reducing pain. - Prophylaxis in hematopoietic stem cell transplantation: administered to prevent invasive fungal infections during the neutropenic phase of transplant conditioning. - Candida infections in neutropenic patients: provides rapid antifungal activity to reduce infection risk during periods of low white‑blood‑cell counts.

Micafungin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Elevated liver enzymes: transient increase in ALT or AST. - Fever: mild to moderate temperature rise. - Nausea: occasional gastrointestinal discomfort. - Headache: mild headache episodes. - Phlebitis: irritation at the intravenous site. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury with jaundice. - Severe hypersensitivity: anaphylaxis or angioedema. - Hematologic abnormalities: neutropenia or thrombocytopenia. - Renal impairment: acute kidney injury. - Cardiovascular events: hypotension or arrhythmia.

When using Micafungin Sodium, clinicians should observe several precautionary measures to ensure patient safety. - Renal function: assess baseline kidney function and monitor during therapy. - Hepatic function: evaluate liver enzymes before initiation and periodically thereafter. - Drug interactions: review concomitant medications for potential additive hepatotoxicity. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Immunocompromised patients: monitor closely for breakthrough fungal infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin Sodium can interact with other agents, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure may raise toxicity risk. - Rifampin: strong enzyme induction may reduce micafungin levels.

Moderate Interactions (Monitor Closely): - Azole antifungals: potential additive hepatotoxicity. - Statins: monitor liver function due to combined hepatic metabolism. - Warfarin: possible alteration of anticoagulant effect; check INR.